Save up to $25 on Alphagan P 0.1%
Your Treatment

What is ALPHAGAN® P 0.1%?
ALPHAGAN® P 0.1% ophthalmic solution is an FDA-approved eye medication that's proven to lower high eye pressure in patients with open-angle glaucoma or ocular hypertension.

Will ALPHAGAN® P 0.1% cure my open-angle glaucoma?
No. There is no cure for glaucoma. But high eye pressure is a risk factor that can be treated.

How do I use ALPHAGAN® P 0.1%?
Take ALPHAGAN® P 0.1% ophthalmic solution exactly as your eye doctor prescribed. ALPHAGAN® P 0.1% ophthalmic solution may be used with other topical drug products to lower eye pressure. If you are taking more than 1 eye medication, administer them at least 5 minutes apart.

What are the most common side effects of ALPHAGAN® P 0.1%?
The most common side effects of ALPHAGAN® P 0.1% are eye allergies
(allergic conjunctivitis), eye redness (hyperemia), and itchy eyes. If you develop these or other side effects, contact your eye doctor immediately concerning the continued use of ALPHAGAN® P 0.1%. Ten percent to 20% of patients experienced allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Five percent to 9% of patients experienced burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

What can I do to manage my high eye pressure?
You can help manage your high IOP by staying on your medication and using ALPHAGAN® P 0.1% ophthalmic solution exactly as your eye care professional prescribed. You should talk to your eye care professional before you stop using ALPHAGAN® P 0.1%. You should also see your eye care professional for checkups on a regular basis.

Who should NOT use ALPHAGAN® P 0.1%?*
ALPHAGAN® P 0.1% should not be used for neonates and infants (children under the age of 2). You should also not use ALPHAGAN® P 0.1% if you have allergies to any of the ingredients in ALPHAGAN® P 0.1%.

ALPHAGAN® P 0.1% eyedrops can be absorbed by your body, which may be of concern if you have other medical conditions or are taking other drugs.

So, tell your doctor about your other medications, especially:

  • Heart or blood pressure medicines, such as beta-blockers and calcium channel blockers
  • Sedatives
  • Certain types of antidepressants, including those known as "tricyclic antidepressants" and "MAO inhibitors"

It is also very important to tell your doctor if you have:

  • Depression
  • Heart problems
  • Upcoming surgery for your eyes
  • Eye trauma or injury

*These risks are not the only risks associated with ALPHAGAN® P 0.1%. If you experience these or other side effects, you should immediately contact your eye care professional.

INDICATIONS AND USAGE
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Neonates and Infants (under the age of 2 years): ALPHAGAN® P is contraindicated in neonates and infants (under the age of 2 years).
Hypersensitivity Reactions: ALPHAGAN® P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.
See more below.

INDICATIONS AND USAGE
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Neonates and Infants (under the age of 2 years): ALPHAGAN® P is contraindicated in neonates and infants (under the age of 2 years).
Hypersensitivity Reactions: ALPHAGAN® P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.

WARNINGS AND PRECAUTIONS
Potentiation of Vascular Insufficiency: ALPHAGAN® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.
Severe Cardiovascular Disease: Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.
Contamination of Topical Ophthalmic Products After Use: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

DRUG INTERACTIONS
Antihypertensives/Cardiac Glycosides: Because ALPHAGAN® P may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with ALPHAGAN® P is advised.
CNS Depressants: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
Tricyclic Antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP-lowering effect. Caution is advised in patients taking tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines.
Monoamine Oxidase Inhibitors: Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension. Caution is advised in patients taking MAO inhibitors, which can affect the metabolism and uptake of circulating amines.

ADVERSE REACTIONS
Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

Please click here for full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1 (800)-FDA-1088.